Cargando…
Paediatric Inflammatory Bowel Disease: A Multi-Stakeholder Perspective to Improve Development of Drugs for Children and Adolescents
BACKGROUND AND AIMS: Despite recent approvals for new drugs to treat adults with Crohn’s disease or ulcerative colitis, there are only two approved advanced treatment options [infliximab and adalimumab] for children with inflammatory bowel disease [IBD]. There are many potential new therapies being...
Autores principales: | Croft, Nicholas M, de Ridder, Lissy, Griffiths, Anne M, Hyams, Jeffrey S, Ruemmele, Frank M, Turner, Dan, Cheng, Katharine, Lutsar, Irja, Greco, Marco, Gołębiewska, Zuzanna, Laumond, Floriane, Cavaller-Bellaubi, Maria, Elgreey, Adam, Altepeter, Tara A, Pallidis, Chrissi, Norga, Koen, Nelson, Robert, Crandall, Wallace, Vassal, Gilles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024546/ https://www.ncbi.nlm.nih.gov/pubmed/36130314 http://dx.doi.org/10.1093/ecco-jcc/jjac135 |
Ejemplares similares
-
The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World
por: Church, Peter C., et al.
Publicado: (2018) -
Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years’ multi-stakeholder dialogue on improving access in Europe via MoCA
por: Cavaller-Bellaubi, Maria, et al.
Publicado: (2023) -
The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry
por: Aardoom, Martine A, et al.
Publicado: (2021) -
Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment
por: Neyt, Mattias, et al.
Publicado: (2021) -
Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn’s disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course
por: Harris, Rachel E, et al.
Publicado: (2020)